CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
Open Access
- 26 February 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1499590
Abstract
Multiple myeloma (MM) is a malignant disease of plasma cells that accounts for approximately 10% of all hematological malignancies and is characterized by a clonal proliferation of malignant plasma cells in the bone marrow. Numerous therapeutic strategies, including proteasome inhibitors, immunomodulators, monoclonal antibodies against CD38 and autologous stem cell transplantation, have prolonged the median survival of MM patients. Nevertheless, almost all MM patients suffer disease relapses due to drug resistance and eventually die from MM or MM-related complications. Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy strategy for MM and has shown encouraging results in several clinical trials. However, the use of CAR T-cell therapy for the treatment of MM is still associated with several difficulties, including antigen escape, poor persistence, an immunosuppressive microenvironment, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, CAR T-cell-associated encephalopathy syndrome, cytopenia, and infections. In this review, we describe in detail the target antigens of CAR T cells in MM. We also comprehensively discuss recent innovations in the development of CAR T cells to improve clinical efficacy and strategies to overcome the limitations of CAR T-cell therapy in MM.Keywords
This publication has 101 references indexed in Scilit:
- Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myelomaBiomedicine & Pharmacotherapy, 2023
- Current state and next-generation CAR-T cells in multiple myelomaBlood Reviews, 2022
- Expression of activated integrin β7 in multiple myeloma patientsInternational Journal of Hematology, 2021
- Molecular basis of clonal evolution in multiple myelomaInternational Journal of Hematology, 2020
- CAR-T cells in multiple myeloma: current statusmemo - Magazine of European Medical Oncology, 2020
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and managementBlood Reviews, 2019
- Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma TreatmentCancer Cell, 2017
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cellsCancer Immunology, Immunotherapy, 2008
- Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cellsAnnals of Hematology, 1992